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Abstract
Cholesteatoma represents progressive expansion of the
keratinizing squamous epithelium in the middle ear with
subsequent chronic inflammation in subepithelial connective
tissues. The hypothesis was tested that receptor for advanced
glycation endproduct (RAGE) and its ligand, high-mobility
box 1 (HMGB1), are overexpressed in cholesteatoma, and the
RAGE/HMGB1 axis might contribute to its pathogenesis.
Cholesteatoma samples (n=36) and 27 normal skin specimens
were studied by immunohistochemistry (IHC) for HMGB1
and RAGE expression. Effects of HMGB1 signaling on pro-
liferation, migration, cytokine production, and apoptosis of
human immortalized keratinocytes (HaCaTs) and normal
keratinocytes were studied by quantitative reverse transcrip-
tion (qRT)-PCR, IHC,Western blots, and flow cytometry after
cell co-incubation with HMGB1. While all studied tissues
expressed HMGB1, its expression was higher in
cholesteatoma than in normal skin (p<0.0001). All cases of
cholesteatoma also showed elevated RAGE expression levels,
and only 7/27 (26 %) of normal skin specimens were weakly
positive for RAGE. Proliferation and migration of HaCaT
cells incubated with HMGB1 were up-regulated (p<0.05).
HMGB1 also prevented HaCaT cell apoptosis and induced
activation of several molecular signaling pathways in
keratinocytes. The data suggest that in cholesteatoma,
HMGB1 released from stressed or necrotic epithelial cells
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and binding to RAGE overexpressed in keratinocytes initiates
molecular signaling that culminates in pro-inflammatory cy-
tokine release and chronic inflammation.
Key message
& HMGB1 signaling engages multiple activation pathways
in RAGE-positive keratinocytes.
& HMGB1 protects RAGE-positive keratinocytes from
drug-induced apoptosis.
& Keratinocyte proliferation is controlled via RAGE and
HMGB1 molecular signaling.
& Molecular signaling of the HMGB1/RAGE axis contrib-
utes to cholesteatoma pathogenesis.
Keywords RAGE/HMGB1 axis . Keratinocytes .
Cholesteatoma pathogenesis . Inflammation
Introduction
The immune system has evolved to respond not only to
pathogens, but also to signals released from dying cells.
Sensing the presence of pathogens provides an initial signal
for the immune system to respond to the invader [1, 2]. This
process requires the presence of pattern recognition receptors
(PRRs) that detect pathogen-associated molecular patterns
(PAMPs). The best studied of these receptors are Toll-like
receptors (TLRs). The immune system is also able to recog-
nize endogenous danger signals or damage-associated molec-
ular patterns (DAMPs), which involve molecules released by
necrotic or dying cells [3]. When cells die through necrosis,
they induce several molecular pathways. In contrast, apoptotic
cell death induces tolerance [4]. The DAMP superfamily
includes various breakdown products of the extracellular ma-
trix, e.g., the DNA-binding high-mobility box 1 (HMGB1)
protein which has been widely studied [5]. HMGB1 plays a
crucial role in molecular responses to cell damage/necrosis via
activation of the nuclear factor kappa B (NF-κB) transcription
factor and subsequent induction of pro-inflammatory cyto-
kines, interleukin (IL)-1 and tumor necrosis factor alpha
(TNF-α) [6]. The receptor for advanced glycation
endproducts (RAGEs) is the major receptor for DAMPs [4].
RAGE activation via its multiple ligands, including HMGB1,
plays a key role in various diseases, including acute or chronic
inflammatory conditions such as sepsis and diseases such as
rheumatoid arthritis, diabetic nephropathy, and cancer [6–9].
Cholesteatoma is a destructive disease characterized by the
progressive expansion of keratinizing squamous epithelium in
the middle ear and mastoid and chronic inflammatory reaction
of the subepithelial connective tissue which is accompanied
by bone destruction with intracranial extensions. Many theo-
ries of its pathogenesis have been proposed but failed to
provide insights into the molecular background of disease,
prevention, or cure. Cholesteatoma tissue is composed of
proliferating, migrating, and highly keratinizing epithelium
known as the matrix and of subepithelial connective tissue
infiltrated by inflammatory cells, antigen-presenting cells,
fibroblasts, and endothelial cells and known as the perimatrix
[10, 11]. Cholesteatoma tissue is also the source of pro-
inflammatory cytokines such as IL-1, transforming growth
factor alpha (TGF-α), pro-angiogenic factors, and various
enzymes [12–15]. It is suspected but not proven that this
mix of soluble factors activates osteoclasts, which are engaged
in bone destruction [10].
Here, we report for the first time the co-expression of
HMGB1 and RAGE in cholesteatoma tissues and hypothesize
that their molecular interaction resulting in activation of sev-
eral major intracellular signaling pathwaysmay be responsible
for cellular hyperplasia, cell migration, and resistance to apo-
ptosis characteristic of cholesteatoma. Although a Mongolian
gerbil animal model of cholesteatoma has been described [16],
concerns exist about its relevance to human disease [17].
Since we have not been able to establish an in vivo
cholesteatoma model, we have resorted to a series of molec-
ular in vitro studies with human keratinocytes to investigate
the potential role of HMGB1 in the cholesteatoma pathogen-
esis. The results of our ex vivo studies were correlatedwith the
expression in human cholesteatoma tissues of the proteins
shown to be involved in keratinocyte activation and prolifer-
ation. Based on our ex vivo and in situ studies, we propose
that high RAGE expression levels in cholesteatoma tissues
might be the key factor contributing to the disease
progression.
Materials and methods
Patients Thirty-six tissue samples were obtained from 15
females and 21 males diagnosed with acquired middle ear
cholesteatoma who underwent surgery for the first time. The
patients’ ages ranged from 17 to 78 years (median=48). The
presence of pathologically documented middle ear
cholesteatoma in surgically removed tissues was required for
entry into the study. Tissues were fixed in 10% formaldehyde,
and sections stained with hematoxylin–eosin (H + E) were
prepared and evaluated by light microscopy. Control tissues
included noninflammatory skin specimens from the external
auditory canal (n=9) or from the retroauricular area (n=18).
Seven fresh middle ear cholesteatoma tissue samples and
seven control tissue samples were used for protein extraction.
The study was approved by the Local Ethics Committees at
the Poznan University of Medical Sciences (#290/04 to MJS)
and at the Medical University of Bialystok (#R-I-002/89/2010
and #R-I-002/125/2011 to EO) and was conducted as recom-
mended by the Helsinki Declaration.
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Cell cultures Normal human keratinocyte cell line human
immortalized keratinocyte (HaCaT) and Normal Adult Hu-
man Primary Epidermal Kerat inocytes (ATCC®
PCS200011™) were purchased from CLS Cell Lines Service
GmbH (Eppelheim, Germany) and from ATCC, respectively.
HaCaTcells were maintained in RPMI-1640medium (Sigma-
Aldrich Chemie GmbH, Steinheim, Germany) containing
10 % (v/v) heat-inactivated fetal calf serum (FCS), 2 mM
glutamine, 100 mg/mL streptomycin, and 100 U/mL penicil-
lin. Normal Adult Human Primary Epidermal Keratinocytes
were maintained in serum-free Dermal Cell Basal Medium
(ATCC® PCS200030) supplemented with components of the
keratinocyte growth kit (ATCC® PCS200040) that contains
the following growth supplements: bovine pituitary extract
(BPE), rhTGF-α, L-glutamine, hydrocortisone hemisuccinate,
insulin, epinephrine, and apotransferrin. Both cell lines were
grown at 37 °C in a 5 % CO2 humidified atmosphere. Cells in
confluence were harvested, washed twice with phosphate-
buffered saline (PBS), and detached from culture flasks by a
brief treatment with 0.02 % EDTA solution (Sigma-Aldrich
Chemie GmbH).
Reverse transcription and real-time quantitative PCR analysis
of receptor for advanced glycation endproduct and Toll-like
receptor 4 transcripts The primers used for RAGE amplifica-
tion were F=5′-GAAGGGAGTATCTGTGAAGGAA-3′ and
R=5′-AGCTACAGGAGAAGGTGGGA-3′; for TLR4 am-
plification, F=5′-ACAACCTCCCCTTCTCAACCA-3′ and
R=5′-GTGGCTTAGGCTCTGATATGC-3′; and for PBGD
(a housekeeping gene) amplification, F=5′-GCCAAGGACC
AGGACATC-3′ and R=5′-TCAGGTACAGTTGCCCATC-
3′. The quantitative real-time reverse transcription (RT)-PCR
was performed as previously described [18].
Flow cytometryABecton Dickinson flow cytometer equipped
with FACSDiva v6.1.2 software was used to evaluate surface
RAGE expression in cells. To evaluate intracellular HMGB1
expression, cells were permeabilized with saponin (0.1 % in
PBS) for 20 min, washed, and incubated with anti-HMGB1
antibody (Ab). At least 2×104 HaCaT cells were acquired for
analysis. The following Abs were used for staining: polyclon-
al rabbit anti-human HMGB1 (Abcam, Cambridge, USA),
polyclonal rabbit anti-human RAGE (LifeSpan Bioscience
Inc., Seattle, WA, USA), and secondary Ab FITC-labeled
donkey anti-rabbit IgG (Jackson ImmunoResearch Laborato-
ries, Inc., West Grove, USA). Before staining, all Abs, includ-
ing isotype control Ab, were pretitrated to establish optimal
staining dilutions, and the staining was performed as previ-
ously described [18].
Immunohistochemistry The following primary Abs were used
for immunostaining of tissue sections: rabbit polyclonal anti-
human: HMGB1 (Abcam), RAGE (LifeSpan Bioscience
Inc.), phosphorylated Akt (pAkt), pc-Jun, pMAPKp44/p42,
pMEK1/2, pSTAT3, pNF-κβ p65 (all from Cell Signaling
Technology, Danvers, MA, USA), and isotype control IgG
(Dako, Gdynia, Poland). Paraffin sections of normal skin,
cholesteatoma, and head and neck squamous cell cancer
(HNSCC) tissues were handled as previously described [19,
20]. As a positive control, HNSCC tissues were stained for
Akt (pAkt), pc-Jun, pMAPKp44/p42, pMEK1/2, pSTAT3,
and pNF-κβ p65. After standard de-paraffinization, the En-
Vision+ System (Dako) was used for staining according to the
manufacturer’s instructions. Slides were evaluated in a light
microscope (at ×200 or ×400 magnification) or in an inverted
Olympus FluoView 10 laser scanning confocal microscope
under an oil immersion objective. For digital image analysis,
the AnalySIS^B software was used. All stained sections were
analyzed and scored by two independent investigators (M.J.S.
andM.L.) to avoid bias, and the two scores were averaged and
recorded. The sections were scored according to the % of
cholesteatoma tissue staining (positivity <25 %=0, 25–
75 %=50, and >75 %=100). The level of staining intensity
was recorded as none=0, weak=1, moderate=2, or strong=3.
Using these values, the H score was calculated for each
sample by multiplying positivity by intensity.
Silencing of Toll-like receptor 4 expression with lentivirus
particles HMGB1 is a ligand for RAGE; however, it also
activates TLR4, and therefore, to avoid co-signaling, TLR4
was silenced in HaCaT cells using five small hairpin RNA
(shRNA) Lentiviral Clones (Sigma-Aldrich Chemie GmbH)
targeting the NM_003266 sequence. The TLR4 gene KO was
preformed according to the manufacturer’s protocol as previ-
ously described by Pi et al. [21]. The TRC1.5 pLKO.1-puro
Empty Vector Control Transduction Particles (Sigma-Aldrich
Chemie GmbH) and TRC1.5 pLKO.1-puro-CMV-TurboGFP
Positive Control Transduction Particles (Sigma-Aldrich
Chemie GmbH) were used as a missense control and positive
control for measuring transduction efficiency and optimizing
shRNA delivery, respectively.
Treatment of cell lines with high-mobility box 1 Cells were
seeded in wells of 6- or 24-well plates (5×105/mL). HMGB1
(Sigma-Aldrich) was added at the concentrations of 10–
200 ng/mL, and cells were incubated for various time periods.
Cells were also cultured in medium alone or without FCS
(controls). In all experiments, HaCaT cells permanently si-
lenced for TLR4 with lentivirus particles (Sigma-Aldrich)
were used. For functional assays, plates were incubated at
37 °C for 6 to 96 h. Supernatants were collected and stored
frozen at −20 °C for cytokine analyses. Each sample was
evaluated in triplicate.
Blocking of high-mobility box 1 effects In some experiments,
anti-RAGE blocking Abs or isotype control Abs (both from
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R&D Systems Inc., Minneapolis, MN, USA) were used to
determine whether interference with HMGB1 signaling in-
hibits cell proliferation and migration. In preliminary titration
experiments, the Ab concentration of 10 μg/mL was found to
be able to almost completely block HMGB1-mediated effects.
SDS-PAGE and Western blots for signaling pathway compo-
nents in human immortalized keratinocyte cells The Abs used
for immunostaining of phosphoproteins were also used for
Western blots. Rabbit polyclonal anti-GAPDH (FL-335) and
goat anti-rabbit IgG HRP-conjugated Abs were purchased
(Santa Cruz Biotechnology, Santa Cruz, CA, USA). Western
blots were performed as previously described [18] using RIPA
buffer (Sigma-Aldrich Chemie GmbH) supplemented with
Halt Protease and Phosphatase Inhibitors (Thermo Scientific,
Rockford, IL, USA) and PMSF (Sigma-Aldrich Chemie
GmbH). The Western blots were quantified using ImageJ
1.46r software (National Institutes of Health, USA).
Cell proliferation and migration assays Cell proliferation and
migration assays were performed using the xCELLigence
System (Roche Diagnostics GmbH) with RTCA DP Instru-
ment (Roche Diagnostics GmbH) according to the manufac-
turer’s protocol. When the cells entered the logarithmic
growth phase, culture medium was aspirated and replaced
with fresh culture medium ± HMGB1 at the concentration of
10–200 ng/ml. Cell proliferation and migration were continu-
ously monitored every 5 min using the RTCA DP Instrument
via calculation of the “cell index” (to reflect the surface area
covered by the cells) for each plate. Each sample was evalu-
ated in triplicate.
Measurements of cytokines in cell culture supernatants The
quantitative determinations of IL-1β and TNF-α levels in
supernatants were performed using a Cytometric Bead Array
Flex Set (BD Biosciences) and analyzed by a FACSCanto
flow cytometer (BD Biosciences) equipped with Fax Diva
Software, according to the manufacturer’s instructions. IL-8
was detected in supernatants from HaCaT cultures using a
human IL-8 Quantikine ELISA kit (R&D Systems) used as
per the manufacturers’ instructions.
Annexin V binding assaysApoptosis after treatment of HaCaT
cells with HMGB1 followed by incubation with cisplatin was
analyzed by flow cytometry, and Annexin V binding to cells
was measured using an Annexin V kit purchased from
Beckman Coulter as previously described [20].
NF-κB and STAT3 translocation and signaling molecule
phosphorylation To evaluate NF-κB or STAT3 expression
and Akt, c-Jun, MAPK, and MEK1/2 activation, the trans-
location to nucleus of the NF-κB p65 subunit and of STAT3
and pAkt, c-Jun, MAPK, and MEK1/2 expression were
measured in an Olympus FluoView 10 confocal microscope
using HaCaT cells stained with rabbit: anti-human NF-κB
p65 (Santa Cruz Biotechnology) and anti-human STAT3
(Cell Signaling Technology) Abs and Abs specific for
pAkt, c-Jun, MAPKs, and MEK1/2 as previously described
[20].
Statistical analysis Data were summarized by descriptive
statistics. Fisher’s exact tests were used to determine if there
was a difference in RAGE and HMGB1 expression among the
tissue types. Adjustments to p values were made using the
Bonferroni step-down procedure. The paired Student’s t test
was used to evaluate differences between treated vs. untreated
pairs of cell lines. The P value of <0.05 was considered to be
significant.
Results
RAGE and HMGB1 expression in cells and tissues The pres-
ence of epithelium in paraffin sections of normal skin and
cholesteatoma tissues was the requirement for evaluating
RAGE and HMGB1 expression. Using immunohistochemis-
try and Western blot techniques, we found significant differ-
ences in RAGE expression levels between cholesteatoma
epithelium and normal skin epithelium (p<0.0001) (Fig. 1a).
In cholesteatoma tissues, RAGE was detectable in the cyto-
plasm and in cell nuclei (Fig. 1a (6)). In normal skin, RAGE
expression was absent in 74 % of specimens or weak in 26 %
(Fig. 1a (5)). RAGE expression in the normal skin epithelium
was confined to the basal layers (23/27=85 %) or to the basal/
granular layers (4/27=15 %). We also found that RAGE was
expressed in sebaceous glands of normal skin, where its
staining intensity ranged from moderate to strong (data not
shown). RAGE was expressed in all cases of cholesteatoma,
and RAGE staining intensity ranged from moderate to strong
(Fig. 1a (6)). In 31 patients (86 %), the staining intensity was
strong, and in 5 (14 %), it was moderate. In cholesteatoma, all
epithelial layers were RAGE positive. In the dermis, RAGE
expression was confined to single fibroblasts or immune cells
(Fig. 1a (7)). In the cholesteatoma perimatrix, a large number
of inflammatory cells were evident, and these cells (Fig. 1a
(8)) as well as endothelial cells (not shown) were strongly
RAGE positive.
We also observed significant differences in HMGB1 ex-
pression between normal skin and cholesteatoma tissues
(p<0.0001). In normal skin, HMGB1 was expressed in all
viable nucleated cells (Fig. 1a (9)) and was not expressed
extracellularly. In cholesteatoma tissues, HMGB1 was also
expressed in all viable and nucleated cells in the matrix and
perimatrix. However, abundant extracellular accumulations of
HMGB1 were also found in the debris released from necrotic
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cells (Fig. 1a (10)). Figure 1b summarizes the differences in
RAGE and HMGB1 expression between normal skin epithe-
lium and cholesteatoma. No differences in RAGE and
HMGB1 expression vs. clinical advance or localization of
cholesteatoma in the middle ear were found.
In preliminary experiments, immunohistochemistry (IHC)
for HMGB1 was performed using a variety of normal human
tissues rich in inflammatory infiltrates such as oral mucosa,
intestine, or nasal polyps of patients with chronic
rhinosinusitis and also tumor issues such as HNSCC. HMGB1
was found to be expressed in all of these tissues (Fig. 2).
Using quantitative reverse transcription (qRT)-PCR and
flow cytometry, messenger RNA (mRNA) and protein for
RAGE and HMGB1 were found to be expressed in HaCaT
cells (Fig. 1c) and in Normal Adult Human Primary Epi-
dermal Keratinocytes (data not shown). In fact, the levels of
expression for RAGE and HMGB1 were comparable in
both lines.
Fig. 1 RAGE, HMGB1, and TLR4 expression in normal skin,
cholesteatoma, and the cell line. a (1) normal skin of external auditory
canal, H + E staining (×200); (2) cholesteatoma tissue, H + E staining
(×200); (3) isotype control in normal skin (×200); (4) isotype control in
the cholesteatoma (×200); (5) cytoplasmic RAGE expression in normal
skin epithelium (×200), inset (×600); (6) cytoplasmic RAGE expression
in thematrix of cholesteatoma (×200), inset (×600); (7) RAGE expression
in dermis layer of the skin, single positive cells are present (arrows)
(×400); (8) RAGE expression in the perimatrix of cholesteatoma, numer-
ous positive cells are present (arrows) (×400); (9) nuclear and cytoplas-
mic HMGB1 expression in normal skin epithelium (×200), inset (×600);
and (10) nuclear, cytoplasmic, and extracellular HMGB1 expression in
cholesteatoma matrix (*), in perimatrix (**), and on debris released from
necrotic cells (***) (×200), inset (×600). b Expression of RAGE and
HMGB1 in normal skin vs. cholesteatoma. The sections were scored
according to the % and level of staining intensity of the tissues. The H
score was calculated for each sample as described in “Materials and
methods.” The H scores for RAGE and HMGB1 expression in normal
skin epithelium vs. cholesteatoma tissue are compared. c RAGE and
HMGB1 expression at the mRNA and protein levels was determined in
HaCaT cells by RT-PCR (left) and flow cytometry (right), respectively.
The gray peaks indicate mean fluorescence intensity (MFI) of isotype
control, while the red peaks show MFI of RAGE or HMGB1. d TLR4
mRNA and protein levels in HaCaT cells prior to and post-stable silenc-
ing with the lentiviral vector or silencing with scrambled RNA
(“missense”)
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By qRT-PCR and Western blots, mRNA and protein levels
of TLR4 were measured before and post-stable TLR4 gene
silencing in HaCaT cells. TLR4 expression was decreased by
80 % in HaCaT cells after gene silencing.
High-mobility box 1 promotes molecular signaling, leading to
proliferation, migration, and interleukin-8 secretion by recep-
tor for advanced glycation endproduct-positive keratinocytes
Effects of HMGB1 on cell proliferation were studied in the
cell lines, which were either exposed to HMGB1 at the con-
centration of 100 ng/mL or pretreated with blocking anti-
RAGE Abs. As shown in Fig. 3a, b, HMGB1 significantly
enhanced proliferation of TLR4-silenced HaCaT cells
(p=0.001) and increased their migration (p=0.001). The ef-
fects of HMGB1 on the cell lines were almost completely
abrogated (p=0.001) in HaCaT cells in the presence of
RAGE-specific blocking Abs. These blocking experiments
were repeated using different concentrations of anti-RAGE
antibodies, and they conclusively demonstrated that HMGB1/
RAGE signaling was responsible for the observed effects.
Increased production of IL-8 in supernatants of HaCaT cells
cultured with HMGB1 was observed, and this effect was also
abrogated (p=0.001) in the presence of RAGE-specific
blocking Abs (Fig. 3c). We did not detect other inflammatory
cytokines, e.g., TNF-α or IL-1β in HaCaTsupernatants, either
before or after their co-incubation with HMGB1.
High-mobility box 1 protects receptor for advanced glycation
endproduct-positive keratinocytes from drug-induced apopto-
sis After stimulation with HMGB1 alone, apoptosis levels
Fig. 2 HMGB1 expression in normal tissues, chronic inflammation, and cancer tissues. a Isotype control in normal oral mucosa (×100). b Normal oral
mucosa. c Normal control intestine. d Chronic rhinosinusitis with nasal polyps (×200). e Head and neck squamous cell cancer (×100)
Fig. 3 The effect of HMGB1 on proliferation, migration, and cytokine
production by TLR4-silenced HaCaT cells. Cell proliferation and migra-
tion assays were performed after 72 h of culture using the xCELLigence
System, and IL-8 level was measured by ELISA assay, as described in
“Materials and methods.” HMGB1 (100 ng/mL) induced significant
proliferation, migration, and IL-8 production in HaCaT cells. Antibodies
specific for RAGE almost completely blocked the effects mediated by
HMGB1. The data are from six experiments with each sample run in
triplicate, and the p values confirm significance of the receptor blockade
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remained unchanged in TLR4-silenced HaCaT cells as mea-
sured by Annexin V binding. Apoptosis was decreased
(p<0.05) when HaCaT cells were pretreated with HMGB1
before treatment with cisplatin (Fig. 4a), HaCaT cells treated
with cisplatin as previously described [20] showed an altered
morphology, with many cells undergoing apoptosis (Fig. 4b).
However, the effect of the drug was partially abrogated when
tumor cells were preincubated with HMGB1 (100 ng/mL).
The data suggest that HMGB1 protects RAGE-positive cells
from cisplatin-induced apoptosis.
High-mobility box 1 signaling engages multiple activation
pathways in receptor for advanced glycation endproduct-
positive keratinocytes To evaluate molecular pathways engaged
in the induction of HaCaT cell proliferation, migration, and
resistance/sensitivity to drug-induced apoptosis upon stimula-
tion with HMGB1, components of the PI3K/Akt survival path-
way as well as c-Jun,MAPKp44/p42,MEK1/2, STAT3, and the
NF-κB pathway components were examined. All these mole-
cules were constitutively expressed in the nonphosphorylated
form in TLR4-silenced HaCaT cells and in normal adult human
primary epidermal keratinocytes (Fig. 5a). The phosphorylated
forms of these proteins were either not expressed or only weakly
expressed in HaCaTcells not stimulated with HMGB1 (Fig. 5a).
After HMGB1 stimulation for 10 to 60 min, phosphoprotein
levels dramatically increased in HaCaT cells (Fig. 5a), and this
effect was partially inhibited in the presence of anti-RAGE
blocking Abs (data not shown). As this Ab was shown to
interfere with HMGB1-mediated induction of proliferation, mi-
gration, and survival of RAGE-positive HaCaT cells (see
above), our data suggest that HMGB1-mediated effects are
mediated through phosphorylation of these proteins.
Importantly, the results obtainedwith cell lines corresponded
to the expression of signaling phosphoproteins in tissues. We
found that all cholesteatoma tissues expressed the above-
described phosphoproteins. Further, their expression levels
ranged from moderate to strong (Fig. 5b). In contrast, expres-
sion levels of these phosphoproteins were undetectable or weak
in normal skin (Fig. 5b), except for the pSTAT3 protein which
showed moderate expression level in epithelial cells. This level
of expression corresponded to the baseline expression in
HaCaT cells unstimulated with HMGB1 (Fig. 5a).
High-mobility box 1 induces translocation of nuclear factor
kappa B p65 and STAT3 transcription factors to the nucleus
Next, translocation of a p65 subunit of NF-κB or pSTAT3 to
the cell nucleus was evaluated after stimulation of TLR1-
silenced HaCaT cells with HMGB1 (Fig. 5c). The baseline
translocation levels for p65 subunit and pSTAT3 were first
established in HaCaTcells and found to occur in 15±7 and 9±
3 % (mean±SD) of cells, respectively. After treatment with
HMGB1, the p65 subunit translocation occurred in 49±12 %
of the cells (p<0.05) and the pSTAT3 translocation in 40±
15 % of the cells (Fig. 5c). These effects were partially but
significantly (p<0.01) blocked by anti-RAGE Abs. These
results further indicate that NF-κB and STAT3 pathways
mediate the HMGB1 effects in RAGE-positive cells.
Discussion
Emerging data indicate that chronic ear inflammation is asso-
ciated with the cholesteatoma development and progression.
Fig. 4 Effects of HMGB1 pretreatment on cisplatin-induced apoptosis in
TLR4-silenced HaCaT cells. HaCaT cells were treated with
HMGB1(100 μg/mL). a HMGB1 pretreatment protects cells from apo-
ptosis induced by cisplatin. Cell lines were first incubated ± HMGB1 for
24 h and then with cisplatin (10 μmol/L) for 6 h, stained with Annexin V
and propidium iodide, and examined by flow cytometry. bMorphologic
changes in HaCaT cells incubated ± cisplatin or + HMGB1 and cisplatin.
Magnification ×200. Results are representative of six independent
experiments
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We have reported that TLR2, TLR3, and TLR4 are expressed
in epithelial cells, including human acquired cholesteatoma
and cancer cells [19, 20, 22]. It is also clear that cholesteatoma
growing in a space-limited area of the middle ear can exceed
the capacity of the existing vessel supply. This might result in
molecular changes such as apoptosis [23] or hypoxia and
necrotic cell death within the cholesteatoma tissue, followed
by release of HMGB1. Most likely, it is HMGB1 which
triggers paracrine activation of RAGE expressed in the
cholesteatoma matrix but not (or only weakly) in normal skin.
In this study, we demonstrated for the first time co-
expression of RAGE and its endogenous ligand, HMGB1, in
cholesteatoma. Their co-expression was significantly up-
regulated in cholesteatoma compared to normal skin epitheli-
um. Of special interest is the finding of extracellular accumu-
lations of HMGB1 in cholesteatoma tissues, suggesting that
release of HMGB1 from cells and its abundance contribute to
chronic inflammation. In the microenvironment of middle ear
cholesteatoma, RAGE/HMGB1 signaling might be, at least in
part, responsible for molecular mechanisms that contribute to
the development of the inflammatory disease.
To examine the molecular signaling pathways potentially
involved in cholesteatoma induction, we used an in vitro
HaCaT model. The molecular signaling in this cell line does
not necessarily explain the pathogenesis of cholesteatoma. For
this reason, responses of keratinocytes to HMGB1-induced
signaling were compared to signals and expression patterns
present in vivo, in the cholesteatoma tissues. In the absence of
an in vivo animal model of cholesteatoma, this approach
allowed us, in part, to reconstruct the cellular and molecular
events that are likely to be associated with the disease devel-
opment. In addition, we demonstrated that activation of the
Fig. 5 Expression of signaling molecules in TLR4-silenced HaCaT cells
and in tissue sections and translocation of NF-κB p65 and STAT3 upon
triggering with HMGB1. a Western blots of HaCaT and normal adult
human primary epidermal keratinocytes incubated ± HMGB1 show
phosphorylation of the PI3K/Akt, c-Jun, MAPKp44/p42, MEK1/2,
STAT3, and NF-κB. b Increased levels of all phosphorylated signaling
molecules in cholesteatoma tissue vs. normal skin. HNSCC tissues (the
lowest row) were used as a positive control (×200). c HaCaT cells plated
overnight were stimulated with HMGB1 (100 ng/mL) ± anti-RAGE Ab
for 12 h and then stained using isotype control IgG or antibodies for
NF-κB and pSTAT3, pAkt, pc-Jun, pMAPK, and pMEK1/2, as described
in “Materials and methods.” Control cells were unstimulated. Bar=
20 μm. Results are representative of three independent experiments
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RAGE/HMGB1 signaling axis in normal keratinocytes in-
duced their proliferation and migration, decreased the sensi-
tivity to drug-induced apoptosis, activated pro-survival mole-
cules, and stimulated intracellular kinase signaling pathways
followed by activation of NF-κB and STAT3 transcription
factors. Our results are consistent with previous studies which
showed that topical application of HMGB1 to skin wounds in
mouse models of diabetes enhanced vessel density, accelerat-
ed wound healing, and consistently had chemotactic effects on
skin fibroblasts and keratinocytes in vitro [24]. It is necessary
to stress, however, that RAGE/HMGB1 signaling is not re-
stricted to keratinocytes. HMGB1 expression has been ob-
served by us in normal intestinal mucosa, in chronic
rhinosinusitis, and in tumors rich in inflammatory infiltrates
such as HNSCC (data not shown). HMGB1 is a chaperone,
which has been reported to be present in all nucleated cells and
to be expressed in normal and pathological conditions, includ-
ing inflammation, cancer, and autoimmune disorders [25–27].
Thus, its overexpression and potential involvement in molec-
ular signaling are not specific to cholesteatoma but are man-
ifestations of the inflammatory cascade that HMGB1 sustains
via the HMGB1/RAGE axis.
The PI3K/Akt/NF-κB pathway is now recognized as one of
the critical pathways in regulating cell survival/apoptosis,
migration, and proliferation in pathological conditions such
as chronic inflammation or cancer [8, 9, 20].We demonstrated
that triggering of RAGE by HMGB1 activated Akt, induced
NF-κB p65 translocation, and resulted in increased prolifera-
tion and decreased sensitivity to drug-induced apoptosis in
keratinocytes. In agreement with other reports [1, 14, 15], we
found that levels of pAkt and pNF-κB molecules were signif-
icantly increased and the phosphorylated forms of c-Jun,
MEK1, MEK2, MAPKp44/p42 (Erk1/2), and STAT3 were
overexpressed in cholesteatoma tissue vs. normal skin epithe-
lium. Furthermore, phosphorylation of all the above-listed
molecules was triggered by HMGB1/RAGE interactions in
cell lines and correspondingly also in cholesteatoma tissues.
The abnormal behavior of cholesteatoma epithelium
seems to be related to the presence of infiltrating immune
cells releasing high levels of various cytokines and growth
factors. Although IL-1α and TNF-α were not secreted by
HaCaT cells, HMGB1 triggered IL-8 production in these
cells, confirming previous reports that HMGB1/RAGE in-
teractions can induce IL-8, a cytokine best known for its
pro-inflammatory effects on immune cells [27–29]. We
suggest, therefore, that RAGE and HMGB1 regulate bone
remodeling in chronic inflammation via up-regulation of
the IL-8 production, a mediator of bone destruction, in
tissue samples of cholesteatoma. The role of RAGE/
HMGB1 interactions in bone remodeling has been
reviewed [30], and a higher expression of RAGE within
cholesteatoma perimatrix, which is adjacent to ossicle sur-
face or to other parts of the temporal bone, might be
interpreted as indicative of the RAGE/HMGB1 involve-
ment in this process.
The immune response is critical for the primary defense
against middle ear infections. HMGB1 is released extracellu-
larly in response to stress or necrosis and behaves as a cyto-
kine, promoting inflammation [31]. It is possible that
keratinocyte proliferation is promoted and sustained by
HMGB1 via its interaction with RAGE on keratinocytes. It
is also plausible that RAGE/HMGB1 interactions may trigger
the signaling pathways involved in the regulation of chronic
inflammation as well as bone resorption in cholesteatoma. The
cholesteatoma molecular pathogenesis, growth, and inflam-
mation might be related to the co-expression and functional
interactions between HMGB1 and RAGE. Their molecular
interactions may not be specific to cholesteatoma but, as a
prominent part of the inflammatory milieu, are involved in the
pathogenesis of this middle ear disease. This suggests that
blocking of these interactions might represent a new poten-
tially effective therapy, especially early in disease develop-
ment. A development of an in vivo animal model of
cholesteatoma is crucial for in vivo testing the validity of the
proposed mechanisms.
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